Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rapid Dose Therapeutics (DOSE) signs exclusive manufacturing and distribution agreement with MapleX Naturals Inc
  • The flagship product ‘QuickStrip™’ is a thin, orally dissolvable film delivered quickly into the bloodstream bypassing first-pass metabolism resulting in rapid onset of the active ingredient
  • MapleX products are currently distributed in specialty retail locations across Canada
  • Rapid Dose Therapeutics is a publicly traded Canadian life sciences company providing innovative, proprietary drug delivery technologies
  • Rapid Dose Therapeutics Corp. (DOSE) is up 11.90 per cent and is trading at C$0.24 at 10:48 am ET

Rapid Dose Therapeutics Corp. (DOSE) is a Canadian Life Science company focused on innovative drug and active ingredient delivery solutions.

The flagship product ‘QuickStrip™’ is a thin, orally dissolvable film, infused with an active ingredient delivered quickly into the bloodstream bypassing first-pass metabolism resulting in rapid onset of the active ingredient.

Rapid Dose has entered into an exclusive manufacturing and distribution agreement with MapleX Naturals Inc. (“MapleX”) for its personal care product line of topical creams and lotions.

These ointments are infused with natural ingredients such as hemp and Canadian maple syrup, for sale by Rapid Dose to retailers across North America.

MapleX was a founding shareholder in Consolidated Craft Brands, recently acquired by and amalgamated into a wholly-owned subsidiary of RDT.

MapleX has significant experience “infusing Hemp” extracts (rich in Omega 3,6 and 9) into high-end personal care products to provide a “humectant” that repairs the skin, locks in moisture, regulates oil production, reduces inflammation, and visibly smooths the skin.

MapleX products are currently distributed in specialty retail locations across Canada.

Dave Thompson, CEO of MapleX, commented, “We are excited to enter into this agreement with RDT. As a result, we look forward to providing customers in Canada and later in the United States with our MapleX product line.”

Mark Upsdell, CEO of RDT, commented, “The agreement with MapleX is key to our product line expansion as we continue to grow our health and wellness portfolio of products to augment the opportunities from our ‘QuickStrip™ technology.”

“We have already shipped our first topical products and look forward to seeing them in retailers across Canada in the coming weeks,” added Upsdell.

Rapid Dose Therapeutics is a publicly-traded Canadian life sciences company providing innovative, proprietary drug delivery technologies designed to improve life outcomes and quality.

Rapid Dose Therapeutics Corp. (DOSE) is up 11.90 per cent and is trading at C$0.24 at 10:48 am ET.

More From The Market Herald

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.

" Leveljump Healthcare (TSXV:JUMP) provides Telehospital purchase update

Leveljump Healthcare (JUMP) has provided the following update on its pending acquisition of Telehospital Corp.
Reliq Health Technologies - CEO Dr. Lisa Crossley

" Reliq Health Technologies (TSXV:RHT) commences clinical trials and announces new contracts

Reliq Health Technologies (RHT) announced that its iUGO Care platform will go live in two clinical trials this month involving over 1,000 patients.

" Defence Therapeutics (CSE:DTC) reports that AccuVAC-PTE7 vaccine provides protection from cervical cancer

Defence Therapeutics (DTC) has announced the development of a dual-acting Accum-linked protein vaccine, AccuVAC-PTE7.